<DOC>
	<DOCNO>NCT01196429</DOCNO>
	<brief_summary>This phase II trial study well temsirolimus , carboplatin , paclitaxel first-line therapy work treat patient newly diagnose stage III-IV clear cell ovarian cancer . Temsirolimus may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving temsirolimus combination chemotherapy may effective treatment ovarian cancer .</brief_summary>
	<brief_title>Temsirolimus , Carboplatin , Paclitaxel First-Line Therapy Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess activity study regimen measure proportion patient alive progression-free least 12 month study entry patient newly diagnose stage III IV clear cell ovarian cancer follow population : patient United States ( U.S. ) worldwide ( outside Japan ) patient Japan . II . To compare progression-free survival newly diagnose stage III IV clear cell ovarian cancer patient patient U.S. worldwide ( outside Japan ) versus patient Japan . SECONDARY OBJECTIVES : I . To characterize duration overall survival progression-free survival population . II . To examine frequency severity adverse event assess Common Terminology Criteria Adverse Events ( CTCAE ) version 4 population . III . To estimate rate objective tumor response patient measurable disease . TERTIARY OBJECTIVES : I . To explore whether immunohistochemical ( IHC ) expression component mammalian target rapamycin ( mTOR ) signal pathway ( phosphatase tensin homolog [ PTEN ] , total phosphorylated protein kinase B [ Akt ] , well , ATP-binding cassette , sub-family C [ CFTR/MRP ] , member 3 [ ABCC3 ] [ MRP3 ] , ATPase , H+ transporting , lysosomal accessory protein 1 [ AB CF2 ] , cyclin E , vascular endothelial growth factor [ VEGF ] ) associate outcome , nationality clinical characteristic . II . To explore whether difference differential gene expression profile U.S. worldwide ( outside Japan ) versus Japanese patient . OUTLINE : Patients receive paclitaxel* intravenously ( IV ) 3 hour carboplatin IV 30 minute day 1 temsirolimus IV day 1 8 . Treatment repeat every 3 week 6 course . Patients receive consolidation therapy comprise temsirolimus IV day 1 , 8 , 15 . Treatment repeat every 3 week 11 course absence disease progression unacceptable toxicity . NOTE : * For circumstance docetaxel substitute paclitaxel , docetaxel give IV 1 hour . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cystadenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must stage III IV clear cell ovarian cancer ; primary tumor must least 50 % clear cell histomorphology order eligible ; addition , tumor negative expression Wilms tumor 1 ( WT1 ) antigen estrogen receptor ( ER ) antigen immunohistochemistry ; appropriate tissue section confirm stage histologic classification cell type must send Gynecologic Oncology Group ( GOG ) central pathology review ; immunohistochemical stain slide ER WT1 antigen must also submit GOG pathology review Patients meet preentry requirement Patients must sign approve informed consent authorization permit release personal health information Patients GOG performance status 0 , 1 , 2 Patients must enter 2 12 week initial surgery ; perform combine purpose diagnosis , stag cytoreduction Patients free active infection require antibiotic ( exception uncomplicated urinary tract infection [ UTI ] ) Absolute neutrophil count &gt; = 1,500/mcl Platelets &gt; = 100,000/mcl Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 time institutional upper limit normal ( &lt; 5 time upper limit normal [ ULN ] subject liver metastasis ) Alkaline phosphatase = &lt; 2.5 time institutional upper limit normal ( &lt; 5 time ULN subject liver metastasis ) Creatinine = &lt; 1.5 x institutional upper limit normal , grade 1 per CTCAE v. 4.0 Cholesterol = &lt; 350 mg/dL ( fast ) Triglycerides = &lt; 400 mg/dL ( fast ) Albumin &gt; = 3.0 g/dL Prothrombin time ( PT ) international normalize ratio ( INR ) = &lt; 1.5 ( inrange INR , usually 2 3 , patient stable dose therapeutic warfarin management venous thrombosis include pulmonary thromboembolus ) Partial thromboplastin time ( PTT ) &lt; 1.2 time upper limit normal Neurologic function ( sensory motor ) = &lt; CTCAE grade 1 Patients history invasive malignancy , exception nonmelanoma skin cancer , exclude evidence malignancy present within last five year ; patient also exclude previous cancer treatment contraindicate protocol therapy Patients receive prior radiotherapy portion abdominal cavity pelvis exclude ; prior radiation localize cancer breast , head neck , skin permit , provide complete five year prior registration , patient remain free recurrent metastatic disease Patients receive prior chemotherapy abdominal pelvic tumor include neoadjuvant chemotherapy clear cell ovarian cancer Patients primary peritoneal fallopian tube carcinoma eligible Previous treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) , paclitaxel , carboplatin Patients receive enzymeinducing antiepileptic drug ( enzymeinducing antiepileptic drug [ EIAEDs ] ; e.g. , phenytoin , carbamazepine , phenobarbital ) cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inducer rifampin St. John 's Wort ; use agent potently inhibit CYP3A4 ( hence may raise temsirolimus level ) , ketoconazole , discourage , specifically prohibit ; appropriateness use agent leave physician discretion ; strong CYP3A4 inhibitor prohibit Patients receive investigational agent Patients severely impaired lung function define diffusion lung capacity carbon monoxide ( DLCO ) = &lt; 50 % normal predict value and/or oxygen ( O2 ) saturation = &lt; 88 % rest room air Patients symptomatic congestive heart failure New York Heart Association class III IV , unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction = &lt; 6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant disease Patients active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel Patients maintenance corticosteroid ineligible exception short term use ( few 5 day ) Patients baseline requirement oxygen Patients serious concomitant illness , opinion treat physician , place patient unreasonable risk therapy protocol Patients pregnant nursing ; patient childbearing potential must agree use contraceptive measure study therapy least six month completion study therapy Patients poorly control diabetes</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>